Bronchogen — Research, Dosing & Price Guide

Bronchogen is a Khavinson bioregulator tripeptide (Ala-Glu-Asp) that specifically targets bronchial and pulmonary epithelial tissue. Developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson, it is designed to normalize respiratory mucosa function, support healthy bronchial epithelial cell turnover, and restore mucociliary clearance that declines with aging or chronic respiratory conditions. It is part of the broader family of short bioregulatory peptides with over 30 years of clinical use in Russian gerontology.

As a bioregulator peptide, Bronchogen operates through an epigenetic mechanism fundamentally different from receptor-mediated pharmacology. The tripeptide Ala-Glu-Asp has tissue-specific affinity for chromatin in pulmonary epithelial cells, where it interacts with specific DNA sequences in gene regulatory regions (promoters and enhancers). This interaction modulates the transcription of genes involved in mucociliary clearance, epithelial tight junction integrity, mucin glycoprotein production, and local innate immune defense (secretory IgA, defensins). The Khavinson bioregulatory theory posits that tissues produce specific short peptides as part of their normal regulatory processes, and these peptide levels decline with aging, stress, or disease. By supplementing with exogenous tissue-specific peptides like Bronchogen, the gene expression profile of the target tissue is shifted back toward a younger, healthier phenotype. This 'epigenetic resetting' improves cellular function without pharmacologically overriding normal signaling — a gentle, restorative approach rather than a forceful one.

• Khavinson Institute studies demonstrated normalization of bronchial epithelial function markers (mucociliary clearance rate, epithelial tight junction protein expression) in elderly patients with chronic respiratory conditions.
• Bioregulator peptides including Bronchogen have been used in Russian clinical practice for over 30 years, with safety data from large patient cohorts in gerontological settings.
• Research on short peptides (2–4 amino acids) by the Khavinson group demonstrated tissue-specific gene expression modulation, with Bronchogen's Ala-Glu-Asp sequence showing preferential activity in pulmonary tissue.
• Improved mucociliary clearance markers and secretory IgA levels in bronchial lavage fluid in preclinical models following Bronchogen administration.
• Long-term studies in elderly populations showed reduced frequency of respiratory infections in patients receiving seasonal bioregulator protocols including Bronchogen.

• Standard dose: 10 mg subcutaneous injection daily, administered in the morning.
• Typical cycle: 10–20 days. The short cycle length reflects the epigenetic mechanism — the goal is to reset gene expression, after which the effects persist without continued dosing.
• Maintenance: Repeat the 10–20 day cycle every 3–6 months, or seasonally (before cold/flu season and before allergy season).
• Can be combined with other bioregulators in a comprehensive protocol — e.g., Bronchogen for lungs + Cardiogen for heart + Crystagen for immunity, each run sequentially or concurrently.
• Oral capsule formulations are available at higher doses. Follow manufacturer dosing instructions.
• No specific food timing requirements. Inject subcutaneously in the abdomen or thigh.

Known Side Effects

• Injection site reactions — mild redness or discomfort, uncommon and self-resolving.
• No significant adverse events reported in the published bioregulator literature.
• Allergic reactions are theoretically possible but extremely rare with tripeptide compounds.
• The short treatment cycles (10–20 days) inherently limit adverse event exposure.
• No hormonal effects, no CNS effects, no metabolic disruption reported.

Safety Profile

Bioregulator peptides like Bronchogen have an excellent safety profile supported by decades of clinical use in Russian gerontology. Short peptides (2–4 amino acids) are rapidly metabolized, have minimal immunogenic potential, and work through gentle epigenetic modulation rather than forceful receptor activation. The 10–20 day treatment cycles further minimize risk. Contraindications are minimal: known hypersensitivity to the peptide or excipients, and pregnancy/breastfeeding (as a precaution). Bioregulators do not interact with pharmaceutical medications and do not affect CYP450 metabolism. They are considered safe for elderly populations, which is their primary use case in Russian clinical practice.

Days 1–5: No immediate subjective effects are expected. Bioregulators work through gradual epigenetic modulation, not acute receptor activation. The peptide is beginning to interact with gene regulatory regions in bronchial tissue. Days 6–15: Some users report subtle improvements in breathing ease, reduced mucus production, or improved respiratory comfort. These effects reflect emerging changes in epithelial gene expression. Days 16–20 (end of cycle): The epigenetic 'reset' is establishing. Effects continue to develop and persist after the cycle ends. Weeks 3–12 (post-cycle): Benefits from the bioregulator cycle typically manifest and persist for 3–6 months after the treatment course. Respiratory function improvements, reduced susceptibility to respiratory infections, and improved mucus clearance are commonly reported during this maintenance period.

Prices sourced from peptides.gg marketplace. Prices may vary.